Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €104.91 EUR
Change Today -3.59 / -3.31%
Volume 3.4K
CG3 On Other Exchanges
As of 3:11 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €119.90
52 Week Low
04/24/14 - €50.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.3M
President and Chief Operating Officer
Total Annual Compensation: $666.7K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $645.8K
President of Global Hematology and Oncology
Total Annual Compensation: $753.3K
President of Research & Early Development an...
Total Annual Compensation: $645.8K
Compensation as of Fiscal Year 2013.

celgene corp (CG3) Key Developments

Celgene Corporation announces Phase II Data for Apremilast in Behçet’s Disease Published in New England Journal of Medicine

Celgene Corporation announced that results from a multicenter, randomized, placebo-controlled phase II trial (BCT-001) of apremilast (Otezla®) in patients with Behçet’s disease were published in the April 16 issue of The New England Journal of Medicine. Behçet’s disease is a rare, chronic inflammatory disorder characterized by recurrent oral and genital ulcers, which are considered a hallmark of the disease. Joint inflammation and recurrent skin and eye lesions may also occur. Findings from this study, including the primary endpoint (reduction in mean number of oral ulcers following 12 weeks of treatment), were initially presented at the European League against Rheumatism (EULAR) and the American College of Rheumatology (ACR) annual meetings in 2013 (P<0.001). Findings from the full 24-week treatment phase were also included in the publication. After 12 weeks, patients in the placebo group were crossed over to apremilast treatment, and those in the apremilast arm continued treatment. For those treated with apremilast for the full 24 weeks, the decrease in the mean number of oral ulcers was evident by week 2 and this decrease was sustained through week 24 (0.6). A decrease in pain associated with oral ulcers paralleled this decrease in ulcers over time. Mean pain scores, measured using a visual analog scale, decreased from 54.3 at baseline to 12.0 at week 2 and 9.7 at week 24. In the placebo arm, pain scores were 51.7 at baseline and 29.8 at week 2. At week 24, following 12 weeks of apremilast treatment, mean pain score in this group was 9.7. The safety and tolerability data for apremilast observed in this study were consistent with previously reported data from six other phase III studies of apremilast in psoriatic arthritis or plaque psoriasis.

Celgene Corporation Elects Michael W. Bonney to its Board of Directors

Celgene Corporation announced the election of Michael W. Bonney to its Board of Directors. Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. from June 2003 until his retirement on December 31, 2014. Mr. Bonney currently serves as a director of Alnylam Pharmaceuticals Inc. He is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds.

Celgene Corporation Announces Executive Changes

On April 1, 2015, Celgene Corporation announced that Gerald F. Masoudi will succeed Lawrence V. Stein, who is retiring, as the company's Executive Vice President, General Counsel and Corporate Secretary effective June 1, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €104.91 EUR -3.59

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.29 USD -0.30
Biogen Inc $419.44 USD -9.21
Bristol-Myers Squibb Co $65.35 USD +1.67
Eli Lilly & Co $72.47 USD -1.02
Shire PLC 5,430 GBp -30.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CG3 Industry Range
Price/Earnings 47.4x
Price/Sales 11.8x
Price/Book 13.9x
Price/Cash Flow 40.2x
TEV/Sales 10.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at